Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Epilepsy ll: Types01:22

Epilepsy ll: Types

24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
Seizures l: Introduction01:20

Seizures l: Introduction

27
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
27
Seizures: Classification01:13

Seizures: Classification

2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Seizures ll: Types01:19

Seizures ll: Types

23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Novel epilepsy treatments in clinical development.

Epilepsy & behavior : E&B·2026
Same author

Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

Drugs·2026
Same author

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs.

Epilepsia·2026
Same author

Novel pharmacological therapies in development.

Current opinion in neurology·2026
Same author

Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

Frontiers in pharmacology·2026
Same author

Transcription Factor Binding and Individual Genetic Risk of Valproate Teratogenicity.

Neurology·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 23, 2026

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
04:41

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research

Published on: October 13, 2023

2.1K

:新たな進歩

Solomon L Moshé1, Emilio Perucca2, Philippe Ryvlin3

  • 1Saul R Korey Department of Neurology, Dominick P Purpura Department of Neuroscience and Department of Pediatrics, Laboratory of Developmental Epilepsy, Montefiore/Einstein Epilepsy Management Center, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, NY, USA.

Lancet (London, England)
|September 28, 2014
PubMed
まとめ
この要約は機械生成です。

エピレプシは,世界中で何百万人もの人に影響を及ぼし,障害と高コストを引き起こす. 理解と治療の進歩にもかかわらず,多くの患者は治療に抵抗性を持ち続け,ケアと研究における重大なギャップを強調しています.

さらに関連する動画

Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

関連する実験動画

Last Updated: Apr 23, 2026

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research
04:41

Author Spotlight: Insights into the Techniques and Findings of Recent Advancements in Epilepsy Research

Published on: October 13, 2023

2.1K
Electrophoretic Delivery of &#947;-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

科学分野:

  • 神経学 神経学とは
  • クリニカル・メディシン 臨床医学
  • 公衆衛生は公衆衛生である.

背景:

  • エピレプシは,世界中で6500万人の個人に影響を及ぼし,障害,死亡率,併発性疾患,汚名,経済的負担という大きな課題をもたらしています.
  • 近年,エピレプシーの病理生理学と予後要因の理解が進展しています.
  • これにより,エピレプシーの定義,診断基準,分類システムが更新されました.

研究 の 目的:

  • 現在のエピレプシー管理の状況を見直し,継続的な課題を特定する.
  • 未満たされたニーズを認識しながら,理解と治療における進歩を強調する.

主な方法:

  • エピレプシーの研究と臨床実務における最近の進歩に関する文献レビュー.
  • 抗薬と外科介入の治療結果の分析.
  • 知識,診断,治療,患者サポートにおける既存のギャップの評価.

主要な成果:

  • 20年以上にわたって抗薬の使用量が大幅に増加したにもかかわらず,患者の約3分の1が薬剤耐性を示しています.
  • の手術は,患者の半数以上にとって著しい発作の自由性を提供しますが,未充分に活用されています.
  • 知識,診断,治療,アドボカシー,教育,立法,研究において,持続的なギャップが残っています.

結論:

  • エピレプシーの管理,特に薬剤耐性症例では,依然として大きな課題が残っています.
  • 手術を含む現在の治療方法は,すべての適格な患者に届いていない.
  • エピレプシーのケアと研究における多面的な課題に対処するために,緊急で協調的な行動が求められます.